- Home
- FNLC vs AMRN Comparison
FNLC vs AMRN Comparison
Compare FNLC & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$13.71
Company Overview
Basic Information| Metric | FNLC | AMRN |
|---|---|---|
| Founded | 1864 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 339.8M |
| IPO Year | 1999 | 1993 |
Fundamental Metrics
Financial Performance| Metric | FNLC | AMRN |
|---|---|---|
| Price | $26.33 | $13.71 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 20.9K | ★ 94.8K |
| Earning Date | 01-21-2026 | 10-29-2025 |
| Dividend Yield | ★ 5.60% | N/A |
| EPS Growth | ★ 18.07 | N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | $88,119,000.00 | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.41 | ★ N/A |
| Revenue Growth | ★ 12.70 | N/A |
| 52 Week Low | $22.11 | $7.08 |
| 52 Week High | $28.60 | $20.90 |
Technical Indicators
Market Signals| Indicator | FNLC | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.37 | 39.25 |
| Support Level | $26.20 | $13.48 |
| Resistance Level | $26.73 | $14.49 |
| Average True Range (ATR) | 0.46 | 0.64 |
| MACD | -0.21 | 0.06 |
| Stochastic Oscillator | 6.97 | 24.66 |
Price Performance
Historical Comparison FNLC
AMRN
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.